Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Watch: Allergan And Valeant Sign Deals, But Not With Each Other; All Eyes On Pfizer

Executive Summary

Allergan finds a white knight in Actavis and Valeant finds a plan B in diagnostics firm Nicox. Meanwhile Pfizer pays $850 million up front to license Merck KGAA’s anti-PD-L1 antibody, in the hopes of catching up in the immuno-oncology space, and BioMarin takes on Prosensa and its Duchenne muscular dystrophy candidate after it was abandoned by GSK.


Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts